Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis

Authors

  • Sohail A. Khan,

    1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom
    Search for more papers by this author
  • John A. Kanis,

    Corresponding author
    1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom
    • WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and, Clinical Biochemistry, University of Sheffield Medical School, Sheffield, U.K.
    Search for more papers by this author
  • Samuel Vasikaran,

    1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom
    Search for more papers by this author
  • W. F. Kline,

    1. Merck Research Laboratories, Rahway, New Jersey, U.S.A.
    Search for more papers by this author
  • B. K. Matuszewski,

    1. Merck Research Laboratories, Rahway, New Jersey, U.S.A.
    Search for more papers by this author
  • Eugene V. McCloskey,

    1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom
    Search for more papers by this author
  • Monique N. C. Beneton,

    1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom
    Search for more papers by this author
  • Barry J. Gertz,

    1. Merck Research Laboratories, Rahway, New Jersey, U.S.A.
    Search for more papers by this author
  • David G. Sciberras,

    1. Merck Research Laboratories, Rahway, New Jersey, U.S.A.
    Search for more papers by this author
  • S. D. Holland,

    1. Merck Research Laboratories, Rahway, New Jersey, U.S.A.
    Search for more papers by this author
  • Jane Orgee,

    1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom
    Search for more papers by this author
  • Gillian M. Coombes,

    1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom
    Search for more papers by this author
  • Suzanne R. Rogers,

    1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, United Kingdom
    Search for more papers by this author
  • A. G. Porras

    1. Merck Research Laboratories, Rahway, New Jersey, U.S.A.
    Search for more papers by this author

Abstract

Postmenopausal women with established vertebral osteoporosis were studied for 2 years to determine the terminal elimination half-life and the duration of response to treatment with intravenous alendronate (30 mg) given over 4 days. The urinary excretion of alendronate followed a multiexponential decline. Approximately 50% of the total dose was excreted over the first 5 days, and a further 17% was excreted in the succeeding 6 months. Thereafter, there was a much slower elimination phase with an estimated mean terminal half-life of greater than 10 years (n = 11). Urinary excretion of hydroxyproline and calcium decreased significantly from pretreatment values by day 3, reaching a nadir by 1 week (40% and 67% decrease, respectively). Thereafter, hydroxyproline remained suppressed for the following 2 years. In contrast, urinary calcium excretion returned gradually toward pretreatment values over the first year and during the second year was comparable to pretreatment values. Serum activity of alkaline phosphatase activity decreased over 3 months (23% reduction), increased gradually thereafter, and returned to pretreatment values at month 24. Bone mineral density measured at the spine increased by approximately 5% during the first year and remained significantly higher than pretreatment values at 2 years. We conclude that a short course of high doses of intravenous alendronate is associated with a prolonged skeletal retention of the agent. This open study also suggests that this regimen has a sustained effect on bone turnover persisting for at least 1 year.

Ancillary